Karachi: Kaashif Hussain Siddique, Executive Director of Liven Pharma Limited, has executed a series of significant transactions involving the sale of company shares, as reported in a disclosure under PSX Regulation 5.6.4. The announcement, made on July 15, 2026, provides detailed insights into the transactions that took place over several days in June and July 2026.

Siddique sold a total of 68,570 shares across ten transactions, starting from June 15 and concluding on July 6. The shares were sold at varying rates, ranging from Rs 40.30 to Rs 41.15 per share. Following these sales, Siddique's cumulative shareholding stands at 48.91 million shares, maintaining a consistent cumulative percentage of 43.33% of the company’s shares.

A notable sale occurred on July 6, when Siddique sold 20,000 shares at Rs 40.70 each, followed by another 10,000 shares at Rs 40.31. These transactions were conducted in the ready market form, utilizing the Central Depository Company (CDC) for execution.

According to information available from the Pakistan Stock Exchange (PSX), these transactions are part of regular disclosures required for substantial shareholders and executives of listed companies. The nature of these sales reflects strategic financial decisions by the executive director, aligning with regulatory compliance measures.

The designated market for these transactions is the ready market, highlighting the liquidity and active trading environment for Liven Pharma Limited shares on the PSX. The continuous sale activity by Siddique may draw attention from analysts and investors monitoring insider trading patterns and their potential impact on stock performance.